Shares in GSK fell around 9% this morning after a judge in a Delaware court gave the green light for tens of thousands of lawsuits claiming harm by gastrointestinal drug Zantac to proceed to trial.

GSK says a $2.2bn settlement agreement will resolve 93% of lawsuits claiming that its Zantac drug caused cancer. Skip to main content Saturday 28 June 2025 . BlueSky linkedin youtube rss ...

Controlling the synthesis of semiconductor nanoclusters — or artificial atoms — is a challenge. Now, a programmable method is introduced to create a series of precisely defined semiconductor ...